Immunocore Holdings plc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Immunocore Holdings plc (IMCR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 3.60% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2025-02-26
- Immunocore Holdings plc effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 3.60%.
- Immunocore Holdings plc effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -1.10%.
- Immunocore Holdings plc effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -20.70%.
- Immunocore Holdings plc effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -9.80%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2024-12-31 | 3.60% 10-K · filed 2025-02-26 |
| 2023-12-31 | -1.10% 10-K · filed 2025-02-26 |
| 2022-12-31 | -20.70% 10-K · filed 2025-02-26 |
| 2021-12-31 | -9.80% 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |